Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 263

1.

Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.

Ono T, Harada M, Yamada A, Tanaka M, Takao Y, Tanaka Y, Mine T, Sakamoto K, Nakashima T, Itoh K.

Clin Cancer Res. 2006 Feb 15;12(4):1325-32.

2.

The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.

Kudo-Saito C, Schlom J, Camphausen K, Coleman CN, Hodge JW.

Clin Cancer Res. 2005 Jun 15;11(12):4533-44.

3.

CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.

Hanson HL, Kang SS, Norian LA, Matsui K, O'Mara LA, Allen PM.

J Immunol. 2004 Apr 1;172(7):4215-24.

4.

Mechanism of antitumor effect on mouse hepatocellular carcinoma by intratumoral injection of OK-432, a streptococcal preparation.

Homma S, Sagawa Y, Komita H, Koido S, Nagasaki E, Ryoma Y, Okamoto M.

Cancer Immunol Immunother. 2007 Aug;56(8):1265-74. Epub 2007 Jan 12.

PMID:
17219148
5.

Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4.

Ahmed SU, Okamoto M, Oshikawa T, Tano T, Sasai A, Kan S, Hiroshima T, Ohue H, Moriya Y, Ryoma Y, Saito M, Sato M.

J Immunother. 2004 Nov-Dec;27(6):432-41.

PMID:
15534487
6.

Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles.

Mohamed ER, Naito M, Terasaki Y, Niu Y, Gohara S, Komatsu N, Shichijo S, Itoh K, Noguchi M.

Int J Oncol. 2009 Feb;34(2):529-36.

PMID:
19148489
7.

Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.

Nakatsura T, Komori H, Kubo T, Yoshitake Y, Senju S, Katagiri T, Furukawa Y, Ogawa M, Nakamura Y, Nishimura Y.

Clin Cancer Res. 2004 Dec 15;10(24):8630-40.

8.

The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.

PMID:
16525645
9.

Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles.

Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, Uemura H, Itoh K, Harada M.

Cancer Immunol Immunother. 2007 May;56(5):689-98. Epub 2006 Aug 26.

PMID:
16937115
10.
11.

Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells.

Koido S, Hara E, Homma S, Torii A, Mitsunaga M, Yanagisawa S, Toyama Y, Kawahara H, Watanabe M, Yoshida S, Kobayashi S, Yanaga K, Fujise K, Tajiri H.

J Immunol. 2007 Jan 1;178(1):613-22.

12.

Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells.

Muraoka D, Kato T, Wang L, Maeda Y, Noguchi T, Harada N, Takeda K, Yagita H, Guillaume P, Luescher I, Old LJ, Shiku H, Nishikawa H.

J Immunol. 2010 Sep 15;185(6):3768-76. doi: 10.4049/jimmunol.0903649. Epub 2010 Aug 23.

14.

Identification of the H2-Kd-restricted cytotoxic T lymphocyte epitopes of a tumor-associated antigen, SPARC, which can stimulate antitumor immunity without causing autoimmune disease in mice.

Ikuta Y, Hayashida Y, Hirata S, Irie A, Senju S, Kubo T, Nakatsura T, Monji M, Sasaki Y, Baba H, Nishimura Y.

Cancer Sci. 2009 Jan;100(1):132-7. doi: 10.1111/j.1349-7006.2008.01016.x. Epub 2008 Dec 4.

15.
16.

Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia.

Manki A, Ono T, Uenaka A, Seino Y, Nakayama E.

Cancer Res. 1998 May 1;58(9):1960-4.

17.

Successful tumor eradication was achieved by collaboration of augmented cytotoxic activity and anti-angiogenic effects following therapeutic vaccines containing helper-activating analog-loaded dendritic cells and tumor antigen DNA.

Teramoto K, Kontani K, Fujita T, Ozaki Y, Sawai S, Tezuka N, Fujino S, Itoh Y, Taguchi O, Kannagi R, Ogasawara K.

Cancer Immunol Immunother. 2007 Mar;56(3):331-42. Epub 2006 Aug 5.

PMID:
16896967
18.

HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.

Motomura Y, Ikuta Y, Kuronuma T, Komori H, Ito M, Tsuchihara M, Tsunoda Y, Shirakawa H, Baba H, Nishimura Y, Kinoshita T, Nakatsura T.

Int J Oncol. 2008 May;32(5):985-90.

PMID:
18425324
19.

Both CD4+ and CD8+ T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors.

Mizukami S, Kajiwara C, Ishikawa H, Katayama I, Yui K, Udono H.

Cancer Sci. 2008 May;99(5):1008-15. doi: 10.1111/j.1349-7006.2008.00788.x. Epub 2008 Mar 12.

20.

Expression of SART3 tumor-rejection antigen in gastric cancers.

Niiya F, Nishizaka S, Matsunaga K, Koufuji K, Mori M, Katai H, Yamana H, Itoh K.

Jpn J Cancer Res. 2000 Mar;91(3):337-42.

PMID:
10760694

Supplemental Content

Support Center